Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

NCT: NCT06854328 · RECRUITING

NCT IDNCT06854328
StatusRECRUITING
Start Date2025-06-11
Completion2026-11-01

Brief Summary

Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms in adolescents. The study aims to demonstrate the safety profile of Prism, having no device-related serious adverse events (SAEs), consistent with findings in the adult population, throughout the course of Prism treatment in an adolescent population.

Frequently Asked Questions

What is The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents?

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents is a clinical trial registered under NCT06854328. Current status: RECRUITING.

What is the status of NCT06854328?

The current status of NCT06854328 (The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents) is: RECRUITING.

When did The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents start?

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents started on 2025-06-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.